Table 2. Ongoing Clinical Trials without published results for treatment of Nonalcoholic Steatohepatitis.

Drug	Mechanism of action	Estimated enrollment	Doses	Primary outcome	ClinicalTrials.gov identifier
NGM282	Fibroblast growth factor 19 analogue	250	5 experimental doses	Change in absolute liver fat content at week 24	NCT02443116
CORT118335	Glucocorticoid receptor modulator/mineralocorticoid receptor antagonist	120	600 mg	Change in liver fat content at week 12	NCT03823703
Betaine	Increases S-adenosylmethionine levels	26	20 mg	Change in steatosis, necroinflammatory activity, and fibrosis at 1 year	NCT00586911
Tirzepatide	Gastric inhibitory polypeptide/glucagon-like peptide-1 agonist	196	5 mg, 10 mg, 15 mg	Reversal of NASH with no worsening of fibrosis at week 52	NCT04166773
Atorvastatin, L-carnitine	Atorvastatin: inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase; L-Carnitine: cofactor for β-oxidation	440	Atorvastatin: 20 mg, L-carnitine: 1,000 mg	Improvement in liver stiffness at year 2	NCT01617772
EDP-305	Farnesoid X receptor agonist	134	2 experimental doses	Change in ALT levels at week 12	NCT03421431
TERN-101	Farnesoid X receptor agonist	96	3 experimental doses	Incidence of adverse events	NCT04328077
Solithromycin	Macrolide antibiotic with anti-inflammatory and immunoregulatory properties	10	200 mg	Change in NAS at week 13	NCT02510599
LPCN 1144	Androgen receptor agonist	75	450 mg	Change in hepatic fat fraction at 12 weeks	NCT04134091
Aldafermin	Fibroblast growth factor 19 analogue	152	3 experimental doses	Histologic response at week 24	NCT03912532
GR-MD-02	Galectin-3 inhibitor	162	2 mg/kg, 8 mg/kg	Reduction in hepatic venous pressure gradient at 1 year	NCT02462967

ALT, alanine aminotransferase; NAS, nonalcoholic fatty liver disease activity score; NAS, nonalcoholic steatohepatitis.